Lung cancer has a dismal prognosis and comprises 5.5% of post-transplant malignancies. We explored whether rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer (NSCLC).
Department of Medicine and Transplantation Medicine, Division of Nephrology, The New York Presbyterian Hospital, Weill Cornell Medical Center, New York, USA.